Cardiol Therapeutics (TSE:CRDL) Trading 11.4% Higher – Still a Buy?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price traded up 11.4% during mid-day trading on Thursday . The company traded as high as C$1.81 and last traded at C$1.76. Approximately 138,484 shares were traded during mid-day trading, an increase of 46% from the average daily volume of 95,163 shares. The stock had previously closed at C$1.58.

Cardiol Therapeutics Trading Down 2.9%

The company has a 50-day simple moving average of C$1.61 and a 200 day simple moving average of C$1.57. The firm has a market cap of C$194.81 million, a PE ratio of -4.33 and a beta of 0.30. The company has a current ratio of 4.39, a quick ratio of 6.84 and a debt-to-equity ratio of 0.48.

Cardiol Therapeutics (TSE:CRDL) last issued its quarterly earnings results on Monday, May 11th. The company reported C($0.10) EPS for the quarter. As a group, sell-side analysts forecast that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.